Table 3

Multivariate regression results for incidence of severe immune-related adverse event

	Estimate	SE	Statistic	P value	OR	OR SE
Patient characteristics
Age	−0.02	0.00	−5.49	<0.001	0.98	0.05
Male gender	0.07	0.09	0.76	0.45	1.07	0.15
Charlson Comorbidity Index (excluding cancer)	0.03	0.02	1.61	0.11	1.03	0.23
Immune checkpoint inhibitor use
CTLA-4 therapy	0.29	0.2	1.42	0.16	1.34	0.2
Combination ICI therapy	0.89	0.14	6.18	<0.001	2.44	0.11
Underlying conditions
Other cancer	−0.69	0.16	−4.29	<0.001	0.5	0.03
Melanoma	−0.35	0.14	−2.45	0.01	0.71	0.21
Renal cell carcinoma	−0.35	0.16	−2.17	0.03	0.71	0.11
Regional information
Zip code average income (normalized)	0.04	0.05	0.74	0.46	1.04	0.17
Zip code average unemployment (normalized)	−0.02	0.05	−0.39	0.7	0.98	0.16
East South Central	−0.25	0.3	−0.83	0.41	0.78	0.02
Mid-Atlantic	−0.17	0.15	−1.09	0.28	0.85	0.14
Mountain	−0.08	0.24	−0.32	0.75	0.93	0.19
New England	0.35	0.21	1.71	0.09	1.42	0.34
Pacific	−0.37	0.22	−1.68	0.09	0.69	0.14
South Atlantic	−0.18	0.15	−1.18	0.24	0.84	0.2
West North Central	0.23	0.24	0.96	0.34	1.26	0.12
West South Central	−0.04	0.17	−0.23	0.82	0.96	0.14

Note: reference group is female patients on programmed cell death protein 1 or programmed death-ligand 1 therapy with lung cancer in East North Central Region.
Other cancers include: bladder cancer, colon cancer, head and neck squamous cell carcinoma Hodgkin’s lymphoma, gastric cancer, liver cancer, cervical cancer, and Merkel cell carcinoma.
CTLA-4, cytotoxic T lymphocyte-associated 4; ICI, immune checkpoint inhibitor .